AbbVie Q1 Confirms Skyrizi Momentum, But Wait Rating Intact

What happened

AbbVie's Q1 2026 revenue of $15B (+12.4% YoY) beat estimates, driven by Skyrizi sales surging 30.9%, prompting management to raise EPS guidance. Despite bullish headlines, the DeepValue master report maintains a Wait rating, as the critical test remains whether Rinvoq hits its $10.1B 2026 target and aesthetics stabilizes toward $5.0B. The next two quarters must validate that demand-led share capture, not Humira timing, sustains the ~$67B revenue and ~$18.5B free cash flow algorithm. While Skyrizi's performance is encouraging, the two-product concentration (~42% of revenue) means any miss in Rinvoq or aesthetics could rapidly re-rate the stock. Investors should wait for confirmation of the broader immunology framework before committing capital.

Implication

The Q1 beat reduces downside risk on Skyrizi but does not eliminate concentration risk. The stock trades at 14.2x 2026 EPS with 17% projected growth, offering compelling long-term value if Rinvoq and aesthetics confirm their trajectories. However, with a Wait rating and attractive entry at $210, investors should await further proof of durable immunology growth and aesthetics stabilization before accumulating. The thesis delta is a modest positive, but we require two more quarters of across-the-board execution to upgrade.

Thesis delta

The Q1 report strengthens confidence in Skyrizi's trajectory, supporting the bull case, but does not resolve key risks around Rinvoq payer access and aesthetics recovery. The base case remains dependent on the full immunology framework of $34.5B in 2026, for which this quarter is one data point.